Another study showed that perturbations in plasma lipid content can activate LOX-1 expression and promote inflammatory responses, suggesting that LOX-1 is a potential driver of ASCVD risk in patients with SLE [105]. The gene discussed is OLR1; the disease is systemic lupus erythematosus.